Copegus and Victrelis drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Copegus (ribavirin) and Victrelis (boceprevir). Common drug interactions include thrombocytopenia among females and anaemia among males.
The phase IV clinical study analyzes what interactions people have when they take Copegus and Victrelis. It is created by eHealthMe based on reports of 717 people who take the same drugs from the FDA, and is updated regularly.
What is Copegus?
Copegus has active ingredients of ribavirin. It is often used in hepatitis c. eHealthMe is studying from 15,115 Copegus users. Check the latest studies of Copegus.
What is Victrelis?
Victrelis has active ingredients of boceprevir. It is often used in hepatitis c. eHealthMe is studying from 8,634 Victrelis users. Check the latest studies of Victrelis.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
717 people who take Copegus and Victrelis together, and have interactions are studied.
What are the common drug interactions of Copegus and Victrelis, by gender? *
What are the common drug interactions of Copegus and Victrelis, by age (0-1 to 60+)? *
What are the existing conditions these people have? *
* Approximation only. Some reports may have incomplete information.
Do you take Copegus and Victrelis?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Browse all drug interactions of Copegus and Victrelis:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Copegus:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Victrelis:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Copegus and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Victrelis and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zRelated publications that referenced our studies
- Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .
- Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .
How the study uses the data?
The study uses data from the FDA. It is based on ribavirin and boceprevir (the active ingredients of Copegus and Victrelis, respectively), and Copegus and Victrelis (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Gliclazide and Postherpetic Neuralgia for Men aged 60+ - a second ago
- Gliclazide and Nerve Pain for Men aged 60+ - a second ago
- Gliclazide and Neuralgia for Men aged 60+ - 2 seconds ago
- Drug interactions of Fluconazole and Clofarabine - 4 seconds ago
- Osteoporosis and drugs of ingredients of tamsulosin - 4 seconds ago
- Escitalopram vs. Niravam, side effect and effectiveness comparison - 4 seconds ago
- Aggrastat and Lopressor drug interactions for women aged 60+ - 11 seconds ago
- Could Atripla cause Nephropathy Toxic? - 13 seconds ago
- Could Budesonide cause Rash Macular? - 18 seconds ago
- Drug interactions of Albuterol and Famciclovir - 25 seconds ago